| 1.24 -0.7 (-36.08%) | 11-03 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |  |
|||
| Targets | 6-month : | 2.34  |
1-year : | 3 |
| Resists | First : | 2 |
Second : | 2.56 |
| Pivot price | 2.15 |
|||
| Supports | First : | 1.1 |
Second : | 0.91 |
| MAs | MA(5) : | 1.81 |
MA(20) : | 2.14 |
| MA(100) : | 1.82 |
MA(250) : | 2.19 |
|
| MACD | MACD : | -0.1 |
Signal : | 0 |
| %K %D | K(14,3) : | 16  |
D(3) : | 15 |
| RSI | RSI(14): 26.7 |
|||
| 52-week | High : | 6.22 | Low : | 1.01 |
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and NEUTRAL in mid-long term.[ TCRX ] has closed below the lower bollinger band by 23.1%. Although price has broken the lower band and a downside breakout is possible; the most likely direction for [ TCRX ] is to continue within current trading range. It is unclear right now based on current values. 175.5% wider than normal. The large width of the bands suggest high volatility as compared to its normal range. The bands have been in this wide range for 2 days. This is a sign that the current trend might continue.
| If tomorrow: | Open lower | Open higher |
| High: | 1.48 - 1.49 | 1.49 - 1.5 |
| Low: | 1.08 - 1.09 | 1.09 - 1.1 |
| Close: | 1.23 - 1.24 | 1.24 - 1.25 |
TScan Therapeutics, Inc., a preclinical-stage biopharmaceutical company, develops T cell receptor-engineered T cell therapies for the treatment of patients with cancer. It is developing TSC-100 and TSC-101 for the treatment of patients with hematologic malignancies to eliminate residual leukemia and prevent relapse after hematopoietic stem cell transplantation; and TSC-200, TSC-201, TSC-202, TSC-203, and TSC-204 for the treatment of solid tumors. The company is also developing vaccines for infectious diseases, such as SARS-CoV-2. It has a collaboration and license agreement with Novartis Institutes for BioMedical Research, Inc., to identify novel cancer antigens from the T cells of patients with a certain specific type of cancer. TScan Therapeutics, Inc. was incorporated in 2018 and is headquartered in Waltham, Massachusetts.
Mon, 03 Nov 2025
Tscan Therapeutics stock plunges after pausing solid tumor trial enrollment By Investing.com - Investing.com UK
Mon, 03 Nov 2025
TScan Therapeutics Announces 30% Workforce Reduction, Cash Runway Extension - TradingView
Mon, 03 Nov 2025
TScan Therapeutics Expects $2.3 Million One-Time Charge For Severance During 3 Months Ended Dec 31 - TradingView
Mon, 03 Nov 2025
TScan Therapeutics (NASDAQ: TCRX) extends cash runway to H2 2027; cuts workforce about 30% - Stock Titan
Mon, 27 Oct 2025
TScan Therapeutics’ Long-Term Study: A Closer Look at TCR-T Therapies - TipRanks
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Outperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Underperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 0 (M) |
| Shares Float | 52 (M) |
| Held by Insiders | 4.403e+007 (%) |
| Held by Institutions | 0.2 (%) |
| Shares Short | 1,720 (K) |
| Shares Short P.Month | 0 (K) |
| EPS | -1.4112e+008 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0 |
| Profit Margin | 0 % |
| Operating Margin | -1 % |
| Return on Assets (ttm) | 256.6 % |
| Return on Equity (ttm) | -26.8 % |
| Qtrly Rev. Growth | 6.96e+006 % |
| Gross Profit (p.s.) | 478.68 |
| Sales Per Share | -63.97 |
| EBITDA (p.s.) | -8.65657e+006 |
| Qtrly Earnings Growth | -1.2 % |
| Operating Cash Flow | 0 (M) |
| Levered Free Cash Flow | -126 (M) |
| PE Ratio | -0.01 |
| PEG Ratio | 0 |
| Price to Book value | 0 |
| Price to Sales | -0.02 |
| Price to Cash Flow | 0.39 |
| Dividend | 0 |
| Forward Dividend | 1.68e+006 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|